Yellow Fever Treatment Market by Treatment Type (Vaccines, Antiviral Drugs), and by End-Use Industry (Hospitals, Clinics, Research Laboratories, Others); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Yellow Fever Treatment Market was valued at USD 1.1 billion in 2023 and will surpass USD 2.0 billion by 2030; growing at a CAGR of 8.7% during 2024 - 2030.

The Yellow Fever Treatment Market is driven by the global need for effective management and prevention of yellow fever, a viral hemorrhagic disease transmitted by infected mosquitoes, primarily in tropical regions. With no specific antiviral treatment available, prevention through vaccination plays a key role in controlling the disease. The market is driven by the growing prevalence of yellow fever outbreaks, particularly in regions of Africa, South America, and Southeast Asia. The ongoing demand for vaccines and antiviral drugs reflects both public health efforts to control the spread of yellow fever and the need for rapid responses during outbreaks. The development of new antiviral treatments and improvements in vaccine formulations are anticipated to further expand the market.

The treatment types in the yellow fever market are primarily vaccines and antiviral drugs. Vaccines have been widely used in endemic areas and are the most effective method for preventing yellow fever. However, antiviral drugs, which are still in development, could offer a new option for treating those infected with the virus. The demand for both these treatment types has increased as the global population is becoming more mobile and outbreaks continue to arise in different regions. The market also benefits from increasing awareness about the disease and the importance of vaccination, as well as the collaboration between governments and international organizations to address yellow fever control.

Vaccines Segment Is Largest Owing to Effective Prevention and Global Vaccination Campaigns

The vaccines segment is the largest in the Yellow Fever Treatment Market, owing to their role in prevention and the widespread use of yellow fever vaccines in endemic areas. The yellow fever vaccine has been the cornerstone of prevention efforts, with the World Health Organization (WHO) recommending mass vaccination campaigns in high-risk regions. The vaccine, a live-attenuated form, provides long-term immunity and has significantly reduced the number of cases and deaths in areas where it has been administered extensively.

Global vaccination campaigns, supported by health organizations such as the WHO and GAVI, have led to an increase in the availability and use of the yellow fever vaccine. The ease of administration, long-lasting immunity, and relatively low cost make it the most effective measure to combat the disease, contributing to its dominance in the market. As outbreaks continue to occur, the demand for yellow fever vaccines is expected to remain high, particularly in areas with limited access to healthcare or where outbreaks are more frequent, ensuring the segment’s continued growth.

Hospitals Are Largest End-Use Industry Owing to Primary Treatment Facilities for Infected Individuals

Hospitals represent the largest end-use industry in the Yellow Fever Treatment Market, as they are the primary healthcare facilities for treating individuals who have been diagnosed with yellow fever. While there is no specific treatment for yellow fever, hospitals are where patients receive supportive care, which includes managing symptoms such as dehydration, fever, and bleeding. In severe cases, patients may require intensive care, further driving the demand for hospital-based treatment.

Given the critical role hospitals play in managing outbreaks and providing immediate care to infected individuals, they remain a central hub for yellow fever management. In areas where yellow fever is endemic, hospitals are equipped to handle both preventive vaccination programs and the care of infected patients. Additionally, the increasing number of healthcare infrastructure developments in emerging markets is further enhancing the demand for yellow fever-related hospital services, making this segment key to the overall market growth.

Asia-Pacific Region is Rapidly Expanding Due to Increasing Awareness and Healthcare Advancements

The Asia-Pacific (APAC) region is experiencing notable growth in the Yellow Fever Treatment Market, primarily driven by increasing healthcare awareness, improving healthcare infrastructure, and the rise in international travel. Although yellow fever is less prevalent in the APAC region compared to Africa and Latin America, increasing mobility and the potential for imported cases from endemic countries has sparked greater awareness and preparedness in countries like India, China, and Thailand. The expanding international travel network, particularly for tourism and business, has heightened the need for vaccination and treatment, leading to increased demand for yellow fever vaccines and antiviral drugs.

Governments in the APAC region are increasingly prioritizing preventive healthcare, with vaccination campaigns and improved access to healthcare services. The World Health Organization’s support for immunization programs in high-risk areas, such as travelers visiting African countries, has further bolstered market growth. As healthcare systems improve and global health initiatives continue to expand, the APAC region is expected to become one of the fastest-growing markets for yellow fever treatments in the coming years.

Competitive Landscape and Leading Companies

The competitive landscape of the Yellow Fever Treatment Market is shaped by the dominance of major pharmaceutical companies that manufacture vaccines and antiviral drugs. Companies like Sanofi, Merck & Co., and GlaxoSmithKline (GSK) are the key players in the vaccine segment, with Sanofi’s Yellow Fever vaccine being one of the most widely used globally. These companies have established strong distribution networks and collaborate with international organizations like the WHO and GAVI to ensure access to vaccines in high-risk regions.

The antiviral drug segment remains less developed, with only a few experimental treatments currently in the pipeline. As research into antiviral therapies progresses, new players may enter the market, potentially increasing competition. Overall, the Yellow Fever Treatment Market is characterized by strong collaborations between the private sector, governments, and international health organizations, which ensure widespread vaccination efforts and the availability of essential treatment options during outbreaks.

Recent Developments:

• Sanofi S.A. announced the launch of an updated Yellow Fever vaccine with improved efficacy for high-risk populations in endemic areas.
• GlaxoSmithKline received approval for a new Yellow Fever vaccine targeting areas with limited access to healthcare.
• Merck & Co., Inc. partnered with the World Health Organization to distribute Yellow Fever vaccines in sub-Saharan Africa.
• Bharat Biotech expanded its production capacity for Yellow Fever vaccines to meet global demand amid rising outbreaks.
• Emergent BioSolutions Inc. secured funding to develop a new antiviral treatment for Yellow Fever, aiming to reduce morbidity and mortality rates in endemic regions.

List of Leading Companies:

• Sanofi S.A.
• GlaxoSmithKline
• Merck & Co., Inc.
• Johnson & Johnson
• Pfizer Inc.
• Emergent BioSolutions Inc.
• Bharat Biotech International Limited
• Serum Institute of India
• Bio-Manguinhos (Fiocruz)
• Vabiotech
• Valneva SE
• Novartis International AG
• Hainan Shuangcheng Pharmaceuticals
• Zydus Cadila
• Vaxine Pty Ltd

Report Scope: